#Biotech Genentech FDA Accepts Obinutuzumab BLA http://t.co/e53H5Z5MFs
July 04, 2013
Publicité
Genentech announced that the U.S. Food and Drug Administration has accepted its Biologics License Application for obinutuzumab and granted Priority Review for obinutuzumab in the treatment of chronic lymphocytic leukemia, one of the most common forms of blood cancer.